IRIDEX Corporation (IRIX) Actualités

Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management

MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide...

Iridex Comments on Changing Glaucoma Reimbursement Landscape

MOUNTAIN VIEW, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Iridex Reports Third Quarter 2024 Financial Results

MOUNTAIN VIEW, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide...

Form 4 - Statement of changes in beneficial ownership of securities

Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024

MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide...

Form 8-K - Current report

Iridex Appoints Patrick Mercer as Chief Executive Officer

MOUNTAIN VIEW, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report

Form S-3 - Registration statement under Securities Act of 1933

Form 10-Q - Quarterly report [Sections 13 or 15(d)]